Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
63.80    -0.20 (-0.31%)
Bid:
63.50
Ask:
63.80
Spread: 0.30 (0.472%)
Market Cap: £563.63m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

New climate fund launch with Australia's CEFC

30 Mar 2026 14:00

RNS Number : 6344Y
IP Group PLC
30 March 2026
 

FOR RELEASE ON

30 March 2026

 

IP Group announces new fund with Australia's Clean Energy Finance Corporation to support Australian cleantech companies

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and technology companies with the potential to create a better future for all, announces that it has launched the IP Group Climate Catalyst Fund with Australia's Clean Energy Finance Corporation ("CEFC").

The new fund will help scale Australian technologies that can decarbonise hard‑to‑abate industries and has a target size of up to A$150m. The launch demonstrates continued execution of IP Group's strategy to grow private capital under management and accelerate the commercialisation of breakthrough science and technology.

The IP Group Climate Catalyst Fund will target Seed and Series A investments in areas including industrial processes (cement, steel and chemicals); mineral processing and supply chain; heavy transport (aviation, shipping and freight); energy-efficient AI and data centres; agriculture and land use; and dispatchable energy and grid balancing. First close of the fund has been reached with IP Group contributing A$30m and CEFC A$20m as cornerstone investors. Fundraising is underway to bring additional third party investors into the Fund.

In Australia, IP Group's cleantech portfolio includes Hysata, developing the world's most efficient hydrogen electrolyser; Electralith, an innovator in lithium extraction and refining; Optigrid, an asset optimisation platform for grid-scale batteries; and Banksia Minerals Processing, which is developing a novel process for refining copper from challenging ores.

IP Group currently manages over £0.5bn in third‑party capital, including a A$435m mandate for Hostplus, one of Australia's top ten superannuation funds. The IP Group Hostplus Innovation fund, managed by the Group's Australian team, has already supported a range of IP Group portfolio companies including Oxford Nanopore, Genomics, First Light Fusion, Oxa and Hysata, providing additive growth capital as these businesses scale.

Greg Smith, Chief Executive of IP Group, said: "This fund strengthens IP Group's ability to back the breakthrough technologies that will define the next era of decarbonisation. The launch of the Climate Catalyst Fund with the CEFC, alongside the recently announced relationship with Aberdeen in the UK, is clear evidence that we are executing our strategy to grow institutional private capital under management and support the scale-up of high-impact science."

Malcolm Thornton, CEFC Head of Growth Capital, said: "This is a strategic relationship between IP Group Australia and the CEFC that is targeting a USD30-50 trillion global decarbonisation opportunity by investing in Australian-emerging climate technologies. Mobilising private capital directed at decarbonising industry is a huge part of what the CEFC is trying to achieve."

Alistair McCreadie, IP Group Australia CIO, said: "The global race to decarbonise is driving unprecedented demand for breakthrough technologies, and achieving material emissions reductions will require the largest reallocation of capital in modern history, creating a generational investment opportunity. While renewable energy has led the charge, the hard-to-abate sectors (accounting for over 30% of global greenhouse gas emissions) represent the next frontier. These sectors demand transformative innovation, not incremental change."

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Lewis Bendall-Craft

+44 (0) 7931 973950

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, we develop and support some of the world's most exciting businesses in healthtech, deeptech and cleantech. Including through Parkwalk, the UK's largest growth EIS fund manager, we back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

About the CEFC

The CEFC is Australia's specialist climate investor, helping cut emissions in the race towards net zero by 2050. We invest in the latest technologies to generate, store, manage and transmit clean energy. Our discounted asset finance programs help put more Australians on the path to sustainability, in their homes and on the road. CEFC capital is also backing the net zero transformation of our natural capital, infrastructure, property and resources sectors, while providing critical capital for the emerging climate tech businesses of tomorrow. With access to more than A$33 billion from the Australian Government, the CEFC invests with commercial rigour and is governed by an independent board.

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGFFLGFGVZG
Date   Source Headline
3rd Jun 20267:00 amRNSHolding(s) in Company
2nd Jun 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
28th May 20267:00 amRNSHolding(s) in Company
13th May 20265:30 pmRNSNotice of AGM
12th May 20269:10 amRNS-REnterprise reports positive results from P2 trial
11th May 20264:25 pmRNSHolding(s) in Company
11th May 20264:19 pmRNSHolding(s) in Company
7th May 20267:00 amRNSAppointment of Chair Designate
23rd Apr 202612:18 pmRNSDirector/PDMR Shareholding
21st Apr 20267:00 amRNS-RFirst Light announces £25m successful first close
15th Apr 20265:00 pmRNSAnnual Financial Report
14th Apr 20269:25 amRNSHolding(s) in Company
30th Mar 20262:00 pmRNSNew climate fund launch with Australia's CEFC
26th Mar 202610:00 amRNSHolding(s) in Company
25th Mar 20262:00 pmRNSHolding(s) in Company
19th Mar 20265:30 pmRNSHolding(s) in Company
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
13th Mar 20265:45 pmRNSHolding(s) in Company
12th Mar 202611:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSNotice of Results
12th Mar 20269:00 amRNSNotice of Results
4th Mar 20267:00 amRNS-RPortfolio company Oxa raises $103m in Series D
26th Feb 20262:53 pmRNSHolding(s) in Company
26th Feb 20269:30 amRNSHolding(s) in Company
25th Feb 20265:51 pmRNSHolding(s) in Company
11th Feb 20269:01 amRNS-RMicrobiotica announces positive P1b trial results
30th Jan 20267:00 amRNSHolding(s) in Company
29th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 202612:36 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSDirectorate change
14th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20266:25 pmRNSHolding(s) in Company
7th Jan 20262:06 pmRNSPulmocide announces termination of Phase 3 study
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20255:26 pmRNSHolding(s) in Company
4th Dec 20254:13 pmRNSHolding(s) in Company
1st Dec 20255:37 pmRNSTotal Voting Rights
20th Nov 20257:00 amRNSCompletion of share buyback programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:10 pmRNSArtios completes oversubscribed $115m financing
14th Nov 20255:47 pmRNSTransaction in Own Shares
14th Nov 20258:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.